DEM BioPharma CEO David Donabedian (L) and executive chair Jan Skvarka

Long­wood sets an­oth­er 'don't eat me' biotech in­to gear with help of for­mer Tril­li­um CEO Jan Skvar­ka

Jonathan Weiss­man and team are out with a can­cer-fight­ing biotech rid­ing the ap­petite for those so-called “don’t eat me” and “eat me” sig­nals.

The sci­en­tif­ic co-founder — along­side fel­low White­head In­sti­tute col­league Kipp Weiskopf and Stan­ford bi­ol­o­gist Michael Bassik — has launched DEM Bio­Phar­ma with in­cu­ba­tor Long­wood Fund and a crop of oth­er in­vestors.

In all, the nascent, 10-em­ploy­ee biotech has $70 mil­lion to bankroll hema­tol­ogy- and sol­id tu­mor-based pro­grams, in­clud­ing a lead as­set that could en­ter hu­man tri­als in two to three years, CEO David Don­abe­di­an told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.